DOCSLIB.ORG

Citi Pure Growth Europe Long-Short Net TR Series II Index (CIISGRE2)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Citi Pure Growth Europe Long-Short Net TR Series II Index (CIISGRE2) Date: 23-May-21 Index Weights as of monthly rebalance date 12-May-21 Citi Pure Growth Europe Long-Short Net TR Series II Index (CIISGRE2) Long Exposure Short Exposure Constituent Bloomberg Ticker Constituent Name Weight(%) Constituent Bloomberg Ticker Constituent Name Weight(%) 1 AAL LN Equity Anglo American Plc 1.62% 1 1COV GY Equity Covestro AG -0.89% 2 ACA FP Equity Credit Agricole SA 1.37% 2 ABBN SE Equity ABB LTD-REG -0.31% 3 ADM LN Equity Admiral Group 0.09% 3 ABF LN Equity Associated British Foods -0.62% 4 ADS GY Equity Adidas AG 1.01% 4 ABN NA Equity ABN AMRO Group NV -1.24% 5 ADYEN NA Equity Adyen NV 2.43% 5 AC FP Equity Accor -1.54% 6 AD NA Equity Ahold NV 0.61% 6 ADEN SE Equity ADECCO GROUP AG-REG -0.49% 7 AHT LN Equity Ashtead Group 0.24% 7 AENA SQ Equity AENA SA -1.05% 8 ALC SE Equity ALCON AG CHF0.04 0.70% 8 AGN NA Equity Aegon NV -0.71% 9 ALFA SS Equity Alfa Laval AB 0.11% 9 AI FP Equity Air Liquide -0.69% 10 ALO FP Equity Alstom 0.45% 10 AKZA NA Equity AKZO NOBEL NV EUR0.50(POST REV SPLIT) -0.37% 11 AMBUB DC Equity Ambu A/S 1.41% 11 ALV GY Equity Allianz SE -0.79% 12 AMP IM Equity Amplifon SpA 0.45% 12 AMS SQ Equity Amadeus IT Hldg SA -1.78% 13 ANTO LN Equity Antofagasta Hldgs 1.62% 13 VNA GY Equity Deutsche Annington Immobilien -0.27% 14 ASM NA Equity ASM Intl 0.65% 14 ASSAB SS Equity Assa Abloy B -1.11% 15 ASML NA Equity ASML Holding NV 0.82% 15 ATCOA SS Equity Atlas Copco AB A -0.68% 16 ATO FP Equity AtoS 0.51% 16 ATCOB SS Equity Atlas Copco AB B -0.66% 17 AZN LN Equity AstraZeneca Plc 0.38% 17 AV/ LN Equity Aviva -0.07% 18 BA/ LN Equity BAE Systems Plc 0.59% 18 BARC LN Equity Barclays -0.02% 19 BAER SE Equity JULIUS BAER GROUP LTD 0.83% 19 BBVA SQ Equity Banco Bilbao Vizcaya Argentaria SA -1.38% 20 BARN SE Equity Barry Callebut AG Reg 0.43% 20 BDEV LN Equity Barratt Developments -0.89% 21 BATS LN Equity British American Tobacco Plc 0.30% 21 BEI GY Equity Beiersdorf AG -0.53% 22 BIM FP Equity BioMerieux 0.43% 22 PROX BB Equity Belgacom SA -0.57% 23 BHP LN Equity BHP GROUP PLC ORD USD0.50 0.26% 23 BMW GY Equity Bayer Motoren Werke AG (BMW) -0.48% 24 BNP FP Equity BNP Paribas 1.05% 24 BN FP Equity Danone -0.15% 25 BNZL LN Equity Bunzl 1.15% 25 BNR GY Equity Brenntag AG -0.96% 26 BVI FP Equity Bureau Veritas SA 0.39% 26 BOL SS Equity BOLIDEN AB NPV -0.42% 27 CA FP Equity Carrefour SA 0.37% 27 BP/ LN Equity BP -0.76% 28 CFR SE Equity CIE FINANCIERE RICHEMONT-REG 0.84% 28 BT/A LN Equity BT Group -1.21% 29 CLNX SQ Equity Cellnex Telecom SA 2.43% 29 CABK SQ Equity CaixaBank -0.21% 30 CNHI IM Equity CNH Industrial 1.66% 30 CAP FP Equity Cap Gemini SA -0.19% 31 CPR IM Equity Davide Campari Group Milano SpA 0.27% 31 CARLB DC Equity Carlsberg AS B -0.22% 32 CRDA LN Equity Croda Intl 0.05% 32 CBK GY Equity Commerzbank AG -1.00% 33 CRH ID Equity CRH ORD EUR0.32 0.22% 33 CHR DC Equity Christian Hansen Holding A/S -1.08% 34 CS FP Equity AXA 1.16% 34 CLN SE Equity Clariant AG -1.24% 35 CSGN SE Equity CREDIT SUISSE GROUP AG-REG 0.73% 35 COLOB DC Equity Coloplast AS B -1.12% 36 DANSKE DC Equity Danske Bank A/S 0.54% 36 CON GY Equity Continental AG -1.51% 37 DBK GY Equity Deutsche Bank AG 2.43% 37 CPG LN Equity Compass Group -1.14% 38 DCC LN Equity DCC ORD EUR0.25 0.19% 38 DB1 GY Equity Deutsche Boerse AG -0.15% 39 DIM FP Equity Sartorius Stedim Biotech 1.67% 39 ORSTED DC Equity Orsted A/S -0.78% 40 DPW GY Equity Deutsche Post AG 0.07% 40 DGE LN Equity Diageo Plc -0.14% 41 DSV DC Equity Dsv A/S 1.23% 41 DHER GY Equity DELIVERY HERO AG -0.67% 42 DTE GY Equity Deutsche Telekom 0.41% 42 DNB NO Equity DNB ASA -0.61% 43 EBS AV Equity Erste Group Bank AG 0.55% 43 DSM NA Equity Koninklijke DSM NV -0.02% 44 ELE SQ Equity Endesa SA 1.39% 44 DSY FP Equity Dassault Systemes SA -0.89% 45 ENR GY Equity Siemens Energy AG 1.14% 45 DWNI GY Equity Deutsche Wohnen AG BR -0.15% 46 EO FP Equity Faurecia 0.67% 46 AIR FP Equity EADS NV-Euro Aero Defense -1.02% 47 EOAN GY Equity E.ON AG 0.06% 47 EDF FP Equity Electricite de France -0.37% 48 ERF FP Equity EUROFINS SCIENTIFI EUR0.10 1.45% 48 ELUXB SS Equity Electrolux AB B -0.06% 49 EVO SS Equity Evolution Gaming Group AB 2.85% 49 EN FP Equity Bouygues -0.80% 50 EXPN LN Equity Experian Plc 0.35% 50 ENEL IM Equity Enel SpA -0.09% 51 FBK IM Equity FinecoBank Banca Fineco SpA 0.70% 51 ENI IM Equity ENI SpA -1.20% 52 FER SQ Equity Ferrovial SA 0.35% 52 EPIA SS Equity EPIROC AB SER'A'NPV (POST SPLIT) -1.09% 53 FGR FP Equity Eiffage 1.38% 53 ERICB SS Equity ERICSSON LM-B SHS -1.24% 54 FME GY Equity Fresenius Medical 0.03% 54 ESSITYB SS Equity ESSITY AKTIEBOLAG-B -0.27% 55 FR FP Equity Valeo 0.41% 55 EVK GY Equity Evonik Industries -0.78% 56 GMAB DC Equity Genmab AS 1.04% 56 STLA IM Equity FIAT CHRYSLER AUTO EUR0.01 -1.30% 57 GIVN SE Equity GIVAUDAN-REG 0.59% 57 FP FP Equity TOTAL SA -0.02% 58 GLEN LN Equity Glencore International PLC 1.00% 58 FRE GY Equity Fresenius SE & Co KGaA -0.14% 59 GN DC Equity GN Store Nord AS 0.83% 59 G IM Equity Assicurazioni Generali SpA -0.44% 60 GRF SQ Equity Grifols SA 0.35% 60 G24 GY Equity Scout24 AG -0.55% 61 ENGI FP Equity GDF Suez 0.76% 61 GALP PL Equity Galp Energia SGPS SA -0.55% 62 HFG GY Equity HelloFresh SE 1.45% 62 SGRE SQ Equity Gamesa Corp Tecnologica SA -0.49% 63 HMB SS Equity Hennes & Mauritz AB B 0.98% 63 GEBN SE Equity GEBERIT AG-REG -0.38% 64 IBE SQ Equity Iberdrola SA 0.15% 64 GLPG NA Equity Galapagos NV -3.24% 65 IFX GY Equity Infineon Technologies AG 0.04% 65 GSK LN Equity GlaxoSmithKline -0.28% 66 III LN Equity 3I Group 0.60% 66 ENT LN Equity GVC HLDGS PLC ORD EUR0.01 -1.52% 67 IMB LN Equity Imperial Tobacco 0.02% 67 HEI GY Equity HeidelbergCement AG -0.11% 68 INGA NA Equity ING Groep NV 0.20% 68 HEIA NA Equity Heineken NV -0.59% 69 ISP IM Equity Intesa SanPaolo 1.46% 69 HEN3 GY Equity Henkel AG & Co. KGaA Nvtg Prf -0.68% 70 ITX SQ Equity Inditex SA 0.57% 70 HEXAB SS Equity HEXAGON AB SER'B'NPV -1.25% 71 JMAT LN Equity JOHNSON MATTHEY PLC 0.59% 71 HNR1 GY Equity Hannover Ruckversicherungs AG Reg -0.17% 72 KBC BB Equity KBC Group NV 0.24% 72 HSBA LN Equity HSBC Holdings Plc -1.69% 73 KGF LN Equity Kingfisher 0.50% 73 IHG LN Equity INTERCONTL HOTELS ORD GBP0.208521303 -1.82% 74 KGX GY Equity KION Group AG 0.98% 74 INVEB SS Equity INVESTOR AB SER'B'NPV -0.39% 75 KINVB SS Equity KINNEVIK AB SER'B'NPV (POST SPLIT) 0.97% 75 KBX GY Equity Knorr-Bremse AG -0.81% 76 KNIN SE Equity KUEHNE + NAGEL INTL AG-REG 0.05% 76 KER FP Equity PPR SA -0.41% 77 KYG ID Equity Kerry Group A 0.04% 77 KN FP Equity Natixis -1.28% 78 LGEN LN Equity Legal & General Group 0.64% 78 KNEBV FH Equity Kone Corp B -0.13% 79 LOGN SE Equity Logitech International SA 0.03% 79 KPN NA Equity Koninklijke KPN NV -0.14% 80 LONN SE Equity LONZA GROUP AG-REG 0.14% 80 HOLN SE Equity LAFARGEHOLCIM LTD-REG -0.15% 81 LSEG LN Equity London Stock Exchange Plc 0.84% 81 LLOY LN Equity Lloyds Banking Group Plc -1.19% 82 LUNE SS Equity Lundin Petroleum A 2.76% 82 LR FP Equity Legrand Promesses -0.48% 83 MAERSKB DC Equity AP Moller - Maersk AS B 1.86% 83 MB IM Equity Mediobanca SpA -1.23% 84 MC FP Equity LVMH-Moet Vuitton 0.01% 84 MOWI NO Equity Marine Harvest ASA -0.27% 85 ML FP Equity Michelin CGDE B Brown 0.10% 85 MNG LN Equity M&G PLC ORD GBP0.05 -2.02% 86 MONC IM Equity MONCLER SPA 1.09% 86 MRK GY Equity MERCK KGaA -0.52% 87 MTX GY Equity MTU Aero Engines Holding AG 0.20% 87 MT NA Equity ArcelorMittal -0.28% 88 NESTE FH Equity Neste Oil OYJ 0.54% 88 NDA SS Equity NORDEA BANK AB NPV -1.12% 89 NESN SE Equity NESTLE SA-REG 0.30% 89 NG/ LN Equity National Grid PLC -0.31% 90 NHY NO Equity Norsk Hydro AS 1.90% 90 NN NA Equity NN Group NV -0.14% 91 OCDO LN Equity Ocado Group PLC 0.12% 91 NOKIA FH Equity Nokia OYJ -0.38% 92 PGHN SE Equity PARTNERS GROUP HLG CHF0.01 (REGD) 1.03% 92 NOVN SE Equity NOVARTIS AG-REG -0.59% 93 PHIA NA Equity Koninklijke Philips Electronics NV (Royal Philips Electronics) 0.09% 93 NOVOB DC Equity Novo Nordisk AS B -0.65% 94 PRX NA Equity Prosus NV 2.67% 94 NXT LN Equity Next -0.02% 95 PRY IM Equity Prysmian SpA 1.51% 95 NZYMB DC Equity Novozymes AS B -1.05% 96 PUM GY Equity PUMA SE 1.62% 96 OR FP Equity L'Oreal -0.78% 97 RKT LN Equity Reckitt Benckiser Group PLC 0.69% 97 PAH3 GY Equity Porsche Automobil Holding SE -0.83% 98 NWG LN Equity ROYAL BANK OF SCOTLAND GROUP 0.33% 98 PNDORA DC Equity Pandora A/S -0.39% 99 TEP FP Equity Teleperformance 0.73% 99 PSN LN Equity Persimmon -0.06% 100 RDSB LN Equity Royal Dutch Shell PLC B 0.51% 100 PST IM Equity Poste Italiane SpA -0.46% 101 REP SQ Equity Repsol-YPF SA 0.52% 101 PUB FP Equity Publicis Groupe -0.30% 102 RSA LN Equity RSA Insurance Group Plc 0.28% 102 FLTR ID Equity PADDY POWER PLC -0.23% 103 RTO LN Equity Rentokil Initial 1.08% 103 QIA GY Equity QIAGEN AG 0.00% 104 SAMPO FH Equity Sampo Oyj A 2.19% 104 RACE IM Equity FERRARI NV -0.60% 105 SEBA SS Equity SEB-Skand Enskilda Banken A 0.29% 105 RAND NA Equity Randstad Hldgs NV -0.28% 106 SGRO LN Equity SEGRO Plc 0.42% 106 RDSA LN Equity Royal Dutch Shell PLC -0.53% 107 SHBA SS Equity Svenska Handelsbanken A 0.03% 107 REL LN Equity Reed Elsevier -0.31% 108 SIKA SE Equity SIKA AG-BR 0.60% 108 RI FP Equity Pernod-Ricard -0.39% 109 SKFB SS Equity SKF AB B 0.17% 109 RIO LN Equity Rio Tinto Plc -0.18% 110 SREN SE Equity SWISS RE AG 1.55% 110 RMS FP Equity Hermes Intl -1.15% 111 SRT3 GY Equity Sartorius AG Nvtg Prf 0.96% 111 RNO FP Equity Renault SA -0.48% 112 STAN LN Equity Standard Chartered 0.17% 112 ROG SE Equity ROCHE HOLDING AG-GENUSSCHEIN -0.06% 113 STERV FH Equity Stora Enso OYJ R 0.22% 113 RR/ LN Equity Rolls-Royce Holdings Plc -0.32% 114 SWMA SS Equity SWEDISH MATCH NPV 1.23% 114 SAF
Load more

Recommended publications
  • Heidelbergcement Half-Year Financial Report January to June
    Half-Year Financial Report January to June 2020 HeidelbergCement achieves good half-year results for 2020 in challenging environment Weak demand due to coronavirus in second quarter – revenue decreases by 10% in first half of 2020 COPE action plan with high cost savings and preservation of liquidity – result 1) declines only slightly by 2% in the first half of 2020 Group share of net result for the period reduced by non-recurring effect from impairments – adjusted Group share rises by 5% Free cash flow at a strong level – net debt decreases by €1.4 billion Solid start into third quarter but business prospects for second half of 2020 remain uncertain – long-term outlook positive 1) Result from current operations before depreciation and amortisation Overview January to June 2020 January - June €m 2019 1) 2020 Revenue 9,212 8,254 Result from equity accounted investments (REI) 126 98 Result from current operations before depreciation and amortisation (RCOBD) 1) 1,438 1,404 RCOBD margin in % 15.6% 17.0% Result from current operations 1) 754 710 Additional ordinary result -128 -3,490 Earnings before interest and taxes (EBIT) 1) 626 -2,779 Financial result 1) -176 -157 Profit / loss before tax 450 -2,936 Net income / loss from continuing operations 300 -3,075 Net loss from discontinued operations -9 -20 Profit / loss for the period 291 -3,095 Group share of profit / loss 212 -3,133 Investments 501 458 1) Changed due to reclassifications Due to rounding, numbers presented in the Half-Year Financial Report may not add up precisely to the totals provided.
    [Show full text]
  • Genmab Announces Data to Be Presented at 2017 ASCO Annual Meeting
    Genmab Announces Data to be Presented at 2017 ASCO Annual Meeting Media Release 8 abstracts on Genmab programs scheduled for presentation at ASCO Two daratumumab oral presentations and five daratumumab poster presentations Copenhagen, Denmark; April 20, 2017 – Genmab A/S (Nasdaq Copenhagen: GEN) announced today that seven daratumumab abstracts have been accepted for presentation at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, June 2 – 6. These abstracts, submitted by our collaboration partner, Janssen Biotech, Inc., include updates for the POLLUX and CASTOR trials, and the first data for a Phase I study evaluating daratumumab with carfilzomib, lenalidomide and dexamethasone in front line multiple myeloma patients, which will be presented in an oral presentation. In addition, descriptions of the Phase Ib/II study of daratumumab plus atezolizumab in non-small cell lung cancer and of our Phase I/II study with HuMax-AXL-ADC are scheduled for poster presentations at the meeting. The titles of the abstracts are currently available on the ASCO website with the full abstracts scheduled to be published on May 17, 2017. “We are very pleased that, once again, a number of abstracts based on exciting work with Genmab’s innovative therapeutic antibody products have been accepted for presentation at the prestigious ASCO conference,” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab. List of abstracts: Daratumumab: Efficacy Of Daratumumab In Combination with Lenalidomide Plus Dexamethasone (DRd) or
    [Show full text]
  • Genmab's 2020 Capital Markets
    WELCOME Genmab’s 2020 Capital Markets Day November 13, 2020 Webcast Live from Utrecht and Princeton Forward Looking Statement This presentation contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. All statements other than statements of historical facts included in this presentation, including, without limitation, those regarding our financial position, business strategy, plans and objectives of management for future operations (including development plans and objectives relating to our products), are forward looking statements. Such forward looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward looking statements. Such forward looking statements are based on numerous assumptions regarding our present and future business strategies and the environment in which we will operate in the future. The important factors that could cause our actual results, performance or achievements to differ materially from those in the forward looking statements include, among others, risks associated with product discovery and development, uncertainties related to the outcome of clinical trials, slower than expected rates of patient recruitment, unforeseen safety issues resulting from the administration of our products in patients, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors.
    [Show full text]
  • Factset-Top Ten-0521.Xlsm
    Pax International Sustainable Economy Fund USD 7/31/2021 Port. Ending Market Value Portfolio Weight ASML Holding NV 34,391,879.94 4.3 Roche Holding Ltd 28,162,840.25 3.5 Novo Nordisk A/S Class B 17,719,993.74 2.2 SAP SE 17,154,858.23 2.1 AstraZeneca PLC 15,759,939.73 2.0 Unilever PLC 13,234,315.16 1.7 Commonwealth Bank of Australia 13,046,820.57 1.6 L'Oreal SA 10,415,009.32 1.3 Schneider Electric SE 10,269,506.68 1.3 GlaxoSmithKline plc 9,942,271.59 1.2 Allianz SE 9,890,811.85 1.2 Hong Kong Exchanges & Clearing Ltd. 9,477,680.83 1.2 Lonza Group AG 9,369,993.95 1.2 RELX PLC 9,269,729.12 1.2 BNP Paribas SA Class A 8,824,299.39 1.1 Takeda Pharmaceutical Co. Ltd. 8,557,780.88 1.1 Air Liquide SA 8,445,618.28 1.1 KDDI Corporation 7,560,223.63 0.9 Recruit Holdings Co., Ltd. 7,424,282.72 0.9 HOYA CORPORATION 7,295,471.27 0.9 ABB Ltd. 7,293,350.84 0.9 BASF SE 7,257,816.71 0.9 Tokyo Electron Ltd. 7,049,583.59 0.9 Munich Reinsurance Company 7,019,776.96 0.9 ASSA ABLOY AB Class B 6,982,707.69 0.9 Vestas Wind Systems A/S 6,965,518.08 0.9 Merck KGaA 6,868,081.50 0.9 Iberdrola SA 6,581,084.07 0.8 Compagnie Generale des Etablissements Michelin SCA 6,555,056.14 0.8 Straumann Holding AG 6,480,282.66 0.8 Atlas Copco AB Class B 6,194,910.19 0.8 Deutsche Boerse AG 6,186,305.10 0.8 UPM-Kymmene Oyj 5,956,283.07 0.7 Deutsche Post AG 5,851,177.11 0.7 Enel SpA 5,808,234.13 0.7 AXA SA 5,790,969.55 0.7 Nintendo Co., Ltd.
    [Show full text]
  • Second Pre-Clinical Milestone Met in Lundbeck Collaboration - €1 Million Milestone Payment to Genmab
    GENMAB REACHES SECOND MILESTONE IN LUNDBECK COLLABORATION - Second pre-clinical milestone met in Lundbeck collaboration - €1 million milestone payment to Genmab Copenhagen, Denmark; February 10, 2012 – Genmab A/S (OMX: GEN) announced today it had reached the second pre-clinical milestone in the collaboration with H. Lundbeck A/S, triggering a €1 million payment. Genmab has reached the second milestone in the collaboration with H. Lundbeck A/S to create and develop human antibody therapeutics for disorders of the central nervous system (CNS). The milestone triggers a payment of €1 million to Genmab. Under the collaboration with Lundbeck Genmab creates novel human antibodies to three targets identified by Lundbeck and Lundbeck has access to Genmab’s antibody creation and development capabilities, including its state of the art, fully automated pre-clinical antibody screening and characterization capabilities and its proprietary stabilized IgG4 and UniBody therapeutic antibody platforms. Under the terms of the agreement, Genmab received an upfront payment of €7.5 million in October 2010 (approximately DKK 56 million). Lundbeck fully funds the development of the antibodies. If all milestones in the agreement are achieved, the total value of the agreement to Genmab would be approximately €38 million (approximately DKK 283 million), plus single-digit royalties. “We are very pleased to have met the in vitro proof of concept milestone for another target in the Lundbeck collaboration. This partnership is progressing well, with this second milestone coming shortly after we achieved the first preclinical milestone in December last year,” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.
    [Show full text]
  • Heidelbergcement Annual Report 2020
    3 Corporate Governance | Remuneration report Remuneration report The majority of variable remuneration should be linked to the long-term development of the company and paid out after an appropriate period of several years. The absolute The remuneration report contains two parts. The first part development of HeidelbergCement’s share price and the presents the Managing Board remuneration system and the direct comparison with relevant benchmark indices should remuneration of members of the Managing Board for the 2020 play a major role in this context. The long-term nature of financial year, both according to the applicable accounting the variable remuneration components is further supported standards and according to the German Corporate Gover- by the fact that even the termination of a Managing Board nance Code valid in the version of 7 February 2017 and in contract has no influence on the target setting, valuation, parts already valid in the version of 16 December 2019, as and maturity. well as the German Act Implementing the Second Share- 3. Key performance indicators are in accordance with the holders' Rights Directive (Gesetz zur Umsetzung der zweiten Group strategy: The key performance indicators used to Aktionärsrechterichtlinie, ARUG II) of 12 December 2019. determine variable remuneration should be in line with The second part shows the remuneration for the Supervisory HeidelbergCement’s business strategy. Board paid for the 2020 financial year. The system and amount of the Managing Board remunera- Current Managing Board remuneration tion are determined by the Supervisory Board following a system 2020 recommendation by the Personnel Committee. The external adequacy check is based on the size and international activity The current Managing Board remuneration system has been of the Group, its economic and financial situation, and its future applied to all newly and reappointed members of the Manag- prospects.
    [Show full text]
  • Interim Report for the First Quarter of 2020
    Genmab Announces Financial Results for the First Quarter of 2020 May 6, 2020; Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2020 Highlights DARZALEX® (daratumumab) net sales increased approximately 49% compared to the first quarter of 2019 to USD 937 million, resulting in royalty income of DKK 775 million DARZALEX approved in Europe in combination with bortezomib, thalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant U.S. FDA approved TEPEZZA™ (teprotumumab-trbw), developed and commercialized by Horizon Therapeutics, for thyroid eye disease U.S. FDA accepted, with priority review, Novartis’ supplemental Biologics License Application for subcutaneous ofatumumab in relapsing multiple sclerosis Anthony Pagano appointed Chief Financial Officer Anthony Mancini appointed Chief Operating Officer “Despite the unprecedented challenges posed by the coronavirus (COVID-19) pandemic, we will continue to invest in our innovative proprietary products, technologies and capabilities and use our world-class expertise in antibody drug development to create truly differentiated products with the potential to help cancer patients. While Genmab is closely monitoring the developments in the rapidly evolving landscape, we are extremely fortunate to have a solid financial foundation and a fabulous and committed team to carry us through these uncertain times,” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab. Financial Performance First Quarter of 2020 Revenue was DKK 892 million in the first quarter of 2020 compared to DKK 591 million in the first quarter of 2019. The increase of DKK 301 million, or 51%, was mainly driven by higher DARZALEX royalties.
    [Show full text]
  • Investment Portfolio (UNAUDITED) | 01.31.2021 CARILLON CLARIVEST INTERNATIONAL STOCK FUND COMMON STOCKS - 96.4% Shares Value Australia - 6.4% Austal Ltd
    Investment Portfolio (UNAUDITED) | 01.31.2021 CARILLON CLARIVEST INTERNATIONAL STOCK FUND COMMON STOCKS - 96.4% Shares Value Australia - 6.4% Austal Ltd. 15,217 $ 29,697 BHP Group Ltd. 1,577 52,591 Coles Group Ltd. 10,814 149,701 CSL Ltd. 365 75,673 Fortescue Metals Group Ltd. 8,456 139,285 Northern Star Resources Ltd. 6,204 60,038 Resolute Mining Ltd.* 26,683 13,891 Sandfire Resources Ltd. 10,113 36,637 Sonic Healthcare Ltd. 1,960 51,223 Belgium - 0.6% Euronav N.V. 3,933 31,516 UCB S.A. 230 23,817 Denmark - 2.7% AP Moeller-Maersk A/S, Class B 57 117,088 Novo Nordisk A/S, Class B 1,512 105,338 Scandinavian Tobacco Group A/S 2,069 37,460 France - 6.3% BNP Paribas S.A.* 1,287 61,719 Cie Generale des Etablissements Michelin 698 96,189 Constellium SE* 2,500 30,825 Eiffage S.A.* 844 76,608 ENGIE S.A.* 5,396 83,742 Fnac Darty S.A.* 726 40,811 Sanofi 1,307 122,921 Sartorius Stedim Biotech 99 41,449 Societe Generale S.A.* 2,369 44,165 Germany - 8.1% Bayer AG 947 57,315 Daimler AG 2,116 148,615 Deutsche Post AG 2,892 142,850 Deutsche Telekom AG 4,660 82,867 HeidelbergCement AG 980 72,441 Hornbach Holding AG & Co. KGaA 183 17,322 Merck KGaA 816 136,002 Muenchener Rueckversicherungs-Gesellschaft AG 195 51,706 TAG Immobilien AG* 2,175 66,787 Hong Kong - 1.5% CK Hutchison Holdings Ltd.
    [Show full text]
  • Portfolio of Investments
    PORTFOLIO OF INVESTMENTS CTIVP® – Lazard International Equity Advantage Fund, September 30, 2020 (Unaudited) (Percentages represent value of investments compared to net assets) Investments in securities Common Stocks 97.6% Common Stocks (continued) Issuer Shares Value ($) Issuer Shares Value ($) Australia 6.9% Finland 1.0% AGL Energy Ltd. 437,255 4,269,500 Metso OYJ 153,708 2,078,669 ASX Ltd. 80,181 4,687,834 UPM-Kymmene OYJ 36,364 1,106,808 BHP Group Ltd. 349,229 9,021,842 Valmet OYJ 469,080 11,570,861 Breville Group Ltd. 153,867 2,792,438 Total 14,756,338 Charter Hall Group 424,482 3,808,865 France 9.5% CSL Ltd. 21,611 4,464,114 Air Liquide SA 47,014 7,452,175 Data#3 Ltd. 392,648 1,866,463 Capgemini SE 88,945 11,411,232 Fortescue Metals Group Ltd. 2,622,808 30,812,817 Cie de Saint-Gobain(a) 595,105 24,927,266 IGO Ltd. 596,008 1,796,212 Cie Generale des Etablissements Michelin CSA 24,191 2,596,845 Ingenia Communities Group 665,283 2,191,435 Electricite de France SA 417,761 4,413,001 Kogan.com Ltd. 138,444 2,021,176 Elis SA(a) 76,713 968,415 Netwealth Group Ltd. 477,201 5,254,788 Legrand SA 22,398 1,783,985 Omni Bridgeway Ltd. 435,744 1,234,193 L’Oreal SA 119,452 38,873,153 REA Group Ltd. 23,810 1,895,961 Orange SA 298,281 3,106,763 Regis Resources Ltd.
    [Show full text]
  • DWS CROCI International
    Investment Portfolio as of March 31, 2021 (Unaudited) DWS CROCI® International VIP Shares Value ($) Common Stocks 96.0% Australia 9.1% Australia & New Zealand Banking Group Ltd. 84,659 1,814,028 BHP Group Ltd. 110,251 3,815,874 Commonwealth Bank of Australia 4,288 280,930 National Australia Bank Ltd. 62,344 1,234,218 Newcrest Mining Ltd. 15,865 297,603 (Cost $5,536,400) 7,442,653 Belgium 1.6% UCB SA (Cost $1,072,787) 13,795 1,312,687 Denmark 3.0% AP Moller - Maersk AS “B” 870 2,024,140 Novo Nordisk AS “B” 7,052 474,954 (Cost $1,948,110) 2,499,094 Finland 1.0% Fortum Oyj 12,738 340,652 Nokia Oyj* 121,910 486,937 (Cost $695,418) 827,589 France 14.1% Atos SE* 22,260 1,739,792 BNP Paribas SA* 53,894 3,290,488 Credit Agricole SA* 118,678 1,721,985 Engie SA* 79,187 1,127,334 Sanofi 30,370 3,003,484 Television Francaise 1* 80,739 737,194 (Cost $9,733,297) 11,620,277 Germany 8.4% Beiersdorf AG 12,876 1,355,372 Brenntag SE 13,966 1,193,987 Deutsche Boerse AG 4,043 672,742 Deutsche Post AG (Registered) 23,524 1,291,802 Fresenius Medical Care AG & Co. KGaA 7,353 542,699 Fresenius SE & Co. KGaA 10,857 484,249 HeidelbergCement AG 5,007 455,278 Merck KGaA 3,152 539,013 SAP SE 2,641 324,172 (Cost $6,246,907) 6,859,314 Hong Kong 0.7% CLP Holdings Ltd.
    [Show full text]
  • Portfolio of Investments
    PORTFOLIO OF INVESTMENTS Variable Portfolio – Partners International Value Fund, September 30, 2020 (Unaudited) (Percentages represent value of investments compared to net assets) Investments in securities Common Stocks 97.9% Common Stocks (continued) Issuer Shares Value ($) Issuer Shares Value ($) Australia 4.2% UCB SA 3,232 367,070 AMP Ltd. 247,119 232,705 Total 13,350,657 Aurizon Holdings Ltd. 64,744 199,177 China 0.6% Australia & New Zealand Banking Group Ltd. 340,950 4,253,691 Baidu, Inc., ADR(a) 15,000 1,898,850 Bendigo & Adelaide Bank Ltd. 30,812 134,198 China Mobile Ltd. 658,000 4,223,890 BlueScope Steel Ltd. 132,090 1,217,053 Total 6,122,740 Boral Ltd. 177,752 587,387 Denmark 1.9% Challenger Ltd. 802,400 2,232,907 AP Moller - Maersk A/S, Class A 160 234,206 Cleanaway Waste Management Ltd. 273,032 412,273 AP Moller - Maersk A/S, Class B 3,945 6,236,577 Crown Resorts Ltd. 31,489 200,032 Carlsberg A/S, Class B 12,199 1,643,476 Fortescue Metals Group Ltd. 194,057 2,279,787 Danske Bank A/S(a) 35,892 485,479 Harvey Norman Holdings Ltd. 144,797 471,278 Demant A/S(a) 8,210 257,475 Incitec Pivot Ltd. 377,247 552,746 Drilling Co. of 1972 A/S (The)(a) 40,700 879,052 LendLease Group 485,961 3,882,083 DSV PANALPINA A/S 15,851 2,571,083 Macquarie Group Ltd. 65,800 5,703,825 Genmab A/S(a) 1,071 388,672 National Australia Bank Ltd.
    [Show full text]
  • Quarterly Commentary—Artisan Non-U.S. Small-Mid Growth Strategy
    QUARTERLY Artisan Non-U.S. Small-Mid Growth Strategy FactCommentary Sheet As of 30 June 2019 Investment Process We seek long-term investments in high-quality businesses exposed to structural growth themes that can be acquired at sensible valuations in a contrarian fashion and are led by excellent management teams. Investing with Tailwinds We identify structural themes at the intersection of growth and change with the objective of investing in companies having meaningful exposure to these trends. Themes can be identified from both bottom-up and top-down perspectives. High-Quality Businesses We seek future leaders with attractive growth characteristics that we can own for the long term. Our fundamental analysis focuses on those companies exhibiting unique and defensible business models, high barriers to entry, proven management teams, favorable positions within their industry value chains and high or improving returns on capital. In short, we look to invest in small companies that have potential to become large. A Contrarian Approach to Valuation We seek to invest in high-quality businesses in a contrarian fashion. Mismatches between stock price and long-term business value are created by market dislocations, temporary slowdowns in individual businesses or misperceptions in the investment community. We also examine business transformation brought about by management change or restructuring. Manage Unique Risks of International Small- and Mid-Cap Equities International small- and mid-cap equities are exposed to unique investment risks that require managing. We define risk as permanent loss of capital, not share price volatility. We manage this risk by having a long-term ownership focus, understanding the direct and indirect security risks for each business, constructing the portfolio on a well-diversified basis and sizing positions according to individual risk characteristics.
    [Show full text]